555 related articles for article (PubMed ID: 28068319)
1. FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation.
Zhou H; Liu Y; Zhu R; Ding F; Wan Y; Li Y; Liu Z
Oncogene; 2017 Jun; 36(23):3312-3321. PubMed ID: 28068319
[TBL] [Abstract][Full Text] [Related]
2. FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity.
Mei Z; Zhang D; Hu B; Wang J; Shen X; Xiao W
J Biol Chem; 2015 Jun; 290(26):16202-14. PubMed ID: 25944903
[TBL] [Abstract][Full Text] [Related]
3. Stability of F-box protein atrogin-1 is regulated by p38 mitogen-activated protein kinase pathway in cardiac H9c2 cells.
Li JJ; Zhang TP; Meng Y; Du J; Li HH
Cell Physiol Biochem; 2011; 27(5):463-70. PubMed ID: 21691063
[TBL] [Abstract][Full Text] [Related]
4. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation.
Zhao D; Zheng HQ; Zhou Z; Chen C
Cancer Res; 2010 Jun; 70(11):4728-38. PubMed ID: 20484041
[TBL] [Abstract][Full Text] [Related]
5. Endophilin-A Deficiency Induces the Foxo3a-Fbxo32 Network in the Brain and Causes Dysregulation of Autophagy and the Ubiquitin-Proteasome System.
Murdoch JD; Rostosky CM; Gowrisankaran S; Arora AS; Soukup SF; Vidal R; Capece V; Freytag S; Fischer A; Verstreken P; Bonn S; Raimundo N; Milosevic I
Cell Rep; 2016 Oct; 17(4):1071-1086. PubMed ID: 27720640
[TBL] [Abstract][Full Text] [Related]
6. Stratifin Inhibits SCF
Shiba-Ishii A; Hong J; Hirokawa T; Kim Y; Nakagawa T; Sakashita S; Sakamoto N; Kozuma Y; Sato Y; Noguchi M
Clin Cancer Res; 2019 May; 25(9):2809-2820. PubMed ID: 30728155
[TBL] [Abstract][Full Text] [Related]
7. FBXO32 links ubiquitination to epigenetic reprograming of melanoma cells.
Habel N; El-Hachem N; Soysouvanh F; Hadhiri-Bzioueche H; Giuliano S; Nguyen S; Horák P; Gay AS; Debayle D; Nottet N; Béranger G; Paillerets BB; Bertolotto C; Ballotti R
Cell Death Differ; 2021 Jun; 28(6):1837-1848. PubMed ID: 33462405
[TBL] [Abstract][Full Text] [Related]
8. The atypical ubiquitin ligase RNF31 stabilizes c-Myc via epigenetic inactivation of FBXO32 and promotes cancer development.
Chen Z; Ren D; Lv J; Xu Y; Xie M; He X; Shi W; Qian Q; Jing A; Ma X; Qin J; Ding Y; Geng T; Ma J; Liu W; Liu S; Ji J
Cell Signal; 2023 Jul; 107():110677. PubMed ID: 37028779
[TBL] [Abstract][Full Text] [Related]
9. FBXO32 activates NF-κB through IκBα degradation in inflammatory and genotoxic stress.
Meshram SN; Paul D; Manne R; Choppara S; Sankaran G; Agrawal Y; Santra MK
Int J Biochem Cell Biol; 2017 Nov; 92():134-140. PubMed ID: 28970077
[TBL] [Abstract][Full Text] [Related]
10. The tumor suppressor ING3 is degraded by SCF(Skp2)-mediated ubiquitin-proteasome system.
Chen G; Wang Y; Garate M; Zhou J; Li G
Oncogene; 2010 Mar; 29(10):1498-508. PubMed ID: 19935701
[TBL] [Abstract][Full Text] [Related]
11. TSGΔ154-1054 splice variant increases TSG101 oncogenicity by inhibiting its E3-ligase-mediated proteasomal degradation.
Chua HH; Huang CS; Weng PL; Yeh TH
Oncotarget; 2016 Feb; 7(7):8240-52. PubMed ID: 26811492
[TBL] [Abstract][Full Text] [Related]
12. DNMT1-mediated regulating on FBXO32 promotes the progression of glioma cells through the regulation of SKP1 activity.
Quan J; Ma C
Environ Toxicol; 2024 Feb; 39(2):783-793. PubMed ID: 37782699
[TBL] [Abstract][Full Text] [Related]
13. Critical lysine residues of Klf4 required for protein stabilization and degradation.
Lim KH; Kim SR; Ramakrishna S; Baek KH
Biochem Biophys Res Commun; 2014 Jan; 443(4):1206-10. PubMed ID: 24388984
[TBL] [Abstract][Full Text] [Related]
14. FBXO32 targets PHPT1 for ubiquitination to regulate the growth of EGFR mutant lung cancer.
Zhang N; Liao Y; Lv W; Zhu S; Qiu Y; Chen N; Xiao M; Zhang H
Cell Oncol (Dordr); 2022 Apr; 45(2):293-307. PubMed ID: 35411430
[TBL] [Abstract][Full Text] [Related]
15. Destabilization of Krüppel-like factor 4 protein in response to serum stimulation involves the ubiquitin-proteasome pathway.
Chen ZY; Wang X; Zhou Y; Offner G; Tseng CC
Cancer Res; 2005 Nov; 65(22):10394-400. PubMed ID: 16288030
[TBL] [Abstract][Full Text] [Related]
16. Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation.
Tanaka N; Kosaka T; Miyazaki Y; Mikami S; Niwa N; Otsuka Y; Minamishima YA; Mizuno R; Kikuchi E; Miyajima A; Sabe H; Okada Y; Uhlén P; Suematsu M; Oya M
JCI Insight; 2016 Nov; 1(18):e83654. PubMed ID: 27812537
[TBL] [Abstract][Full Text] [Related]
17. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis.
Zhao D; Zhi X; Zhou Z; Chen C
Carcinogenesis; 2012 Jan; 33(1):59-67. PubMed ID: 22045023
[TBL] [Abstract][Full Text] [Related]
18. The E3 ubiquitin ligase SCF(Fbxo7) mediates proteasomal degradation of UXT isoform 2 (UXT-V2) to inhibit the NF-κB signaling pathway.
Spagnol V; Oliveira CAB; Randle SJ; Passos PMS; Correia CRSTB; Simaroli NB; Oliveira JS; Mevissen TET; Medeiros AC; Gomes MD; Komander D; Laman H; Teixeira FR
Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129754. PubMed ID: 33010352
[TBL] [Abstract][Full Text] [Related]
19. SCF
Cai L; Liu L; Li L; Jia L
Cell Signal; 2020 Jan; 65():109440. PubMed ID: 31678254
[TBL] [Abstract][Full Text] [Related]
20. Proteasomal degradation of the KLF5 transcription factor through a ubiquitin-independent pathway.
Chen C; Zhou Z; Guo P; Dong JT
FEBS Lett; 2007 Mar; 581(6):1124-30. PubMed ID: 17320083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
